Development and Characterization of Glipizide Loaded Sustained Release Nanoparticles

Author(s): Rutuja Deshmukh, Mrunal Waghulde, Satyendra Mishra, Jitendra Naik*.

Journal Name: Current Nanomedicine
Formerly Recent Patents on Nanomedicine

Volume 9 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Treating the disease like diabetes is essential due to its wide range of spreading and heredity issues. Glipizide is the commonly used drug for the treatment of diabetes. Glipizide loaded sustained release nanoparticles have been developed to avoid repeated dosing.

Objective: The study aimed to develop glipizide-loaded sustained release nanoparticles and characterize them for different studies.

Methods: The aim of the present study was to develop glipizide-loaded sustained release nanoparticles using different polymers by the solvent evaporation method. The polymers; Eudragit (RS 100) in combination with Polycaprolactone (PCL) were used to encapsulate glipizide. Optimization of all parameters was performed as per Design Expert software by utilizing a 32 full factorial design. The developed nanoparticles were characterized using Fourier transformed infrared spectroscopy, X-ray diffraction, scanning electron microscopy and in-vitro drug release study.

Results: FE-SEM showed that the surface morphology of nanoparticles was smooth and spherical as well as in an oval shape. FTIR shows there is no interaction between polymers and drug. XRD results showed that the crystallinity of pure glipizide reduced from 89.5 to 56.7% when converted into sustained release nanoparticles formulation. Sustained drug release over the period of 12 h was observed due to well encapsulation of glipizide by the polymers.

Conclusion: Glipizide loaded nanoparticles were developed with good encapsulation efficiency using a combination of two different biocompatible polymers. The drug release behavior showed that they can be used to develop the sustained release formulation to reduce the side effect caused by over drug uptake as compared to the conventional formulation.

Keywords: Glipizide, eudragit, polycaprolactone, nanoparticles, drug release, design expert software.

[1]
Natarajan J, Nagavishwakya S. Nanoceria: A novel cytoprotective drug delivery carrier. Curr Nanomed 2017; 7: 111-6.
[2]
Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010; 75(1): 1-18.
[3]
Deshmukh R, Mishra S, Naik J. Preparation and characterization of glipizide loaded eudragit microparticles. Micro Nanosyst 2018; 10(2): 129-36.
[4]
Patil J, Naik J. Carrier based oral nano drug delivery framework: A review. Curr Nanomater 2018; 3: 75-85.
[5]
Nedra Karunaratne D, Ariyarathna R, et al. Nanotechnological strategies to improve water solubility of commercially available drugs. Recent Pat Nanomed 2017; 2: 84-110.
[6]
Thomas G. Polymers and biopolymers as drug delivery systems in nanomedicine. Recent Pat Nanomed 2012; 2: 52-61.
[7]
Gupta S, Sharma P, Gupta M. Leishmaniasis - Drugs, nanotechnology based delivery systems and recent patents survey. Curr Nanomed 2016; 6: 21-42.
[8]
Shegokar R, Muller H, Ismail M, Gohla S. Algal nanosuspensions for dermal and oral delivery. Curr Nanomed 2018; 8: 45-57.
[9]
Rai A, Senapati S, Saraf S, Maiti P. Biodegradable poly (ε-caprolactone) as a controlled drug delivery vehicle of vancomycin for the treatment of MRSA infection. J Mater Chem B Mater Biol Med 2016; 4(30): 5151-60.
[10]
Ali AGS, Ebrahimzadeh MH, Solati-Hashjin M, Abu Osman NA. Polycaprolactone/starch composite: Fabrication, structure, properties, and applications. J Biomed Mater Res A 2015; 103(7): 2482-98.
[11]
Koutroumanis KP, Holdich RG, Georgiadou S. Synthesis and micellization of a pH-sensitive diblock copolymer for drug delivery. Int J Pharm 2013; 455(1-2): 5-13.
[12]
Ulery BD, Nair LS, Laurencin CT. Biomedical applications of biodegradable polymers. J Polym Sci, B, Polym Phys 2011; 49(12): 832-64.
[13]
Cao Z, Dou C, Dong S. Scaffolding biomaterials for cartilage regeneration. J Nanomater 2014; 4: 1-8.
[14]
Williams JM, Adewunmi A, Schek RM, et al. Bone tissue engineering using polycaprolactone scaffolds fabricated via selective laser sintering. Biomaterials 2005; 26(23): 4817-27.
[15]
Zhang Y, Zhuo RX. Synthesis and in-vitro drug release behavior of amphiphilic triblock copolymer nanoparticles based on poly (ethylene glycol) and polycaprolactone. Biomaterials 2005; 26(33): 6736-42.
[16]
Ladd MR, Lee SJ, Stitzel JD, Atala A, Yoo JJ. Co-electrospun dual scaffolding system with potential for muscle-tendon junction tissue engineering. Biomaterials 2011; 32(6): 1549-59.
[17]
Lee SJ, Liu J, Oh SH, et al. Development of a composite vascular scaffolding system that withstands physiological vascular conditions. Biomaterials 2008; 29(19): 2891-8.
[18]
Madeleine A, Vesredard Y. francemorrissette M, prud’homme R., Miscible blends prepared from two crystalline polymers J. Polym Sci Polym PhysB 1983; 21: 233-40.
[19]
Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. Poly-ϵ-caprolactone microspheres and nanospheres: an overview. Int J Pharm 2004; 278(1): 1-23.
[20]
Zhou S, Deng X, Yang H. Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) block copolymers: characterization and their use as drug carriers for a controlled delivery system. Biomaterials 2003; 24(20): 3563-70.
[21]
Wagh P, Gawali A, Naik J. Development of ketoprofen loaded micro-/nanospheres using different polymers. Curr Nanomater 2016; 1(3): 207-14.
[22]
Waghulde M, Naik J. Development and validation of analytical method for vildagliptin encapsulated poly-ε-caprolactone microparticles. Mater Today: Proceeding 2018; 5(1): 958-64.
[23]
Glaessl B, Siepmann F, Tucker I, Rades T, Siepmann J. Mathematical modeling of drug release from Eudragit RS-based delivery systems. J Drug Deliv Sci Technol 2010; 20(2): 127-33.
[24]
Naik J, Waghulde M. Development of vildagliptin loaded Eudragit® microspheres by screening design: in-vitro evaluation. J Pharm Investig 2017; 48: 1-11.
[25]
Lokhande A, Naik J. Effect of solvents, drug/polymer ratio and surfactant concentration on in-vitro characteristic of repaglinide loaded poly (Meth) acrylate nanoparticles. Micro Nanosyst 2015; 7(1): 43-5.
[26]
Vidyadhara S, Sasidhar RL, Balakrishna T, Balaji B, Amrutha R. Formulation and evaluation of controlled release floating microballoons of stavudine. Sci Pharm 2015; 83(4): 671-82.
[27]
Thakral S, Thakral NK, Majumdar DK. Eudragit: a technology evaluation. Expert Opin Drug Deliv 2013; 10(1): 131-49.
[28]
Duarte A, Roy C, Vega-Gonzalez A, Duarte C, Subra-Paternault P. Preparation of acetazolamide composite microparticles by supercritical anti-solvent techniques. Int J Pharm 2007; 9: 132.
[29]
Gavini V, Murthy MS, Rao SK, Kumar KP. Formulation and in-vitro evaluation of buoyant drug delivery system of glipizide using acrylic polymer. JDDT 2014; 46: 107-13.
[30]
Saharan P, Bhatt DC, Saharan SP, Bahmani K. Preparation and characterization of antidiabetic drug loaded polymeric nanoparticles. Pharma Chem 2015; 7(12): 398-404.
[31]
Yadav D, Survase S, Kumar N. Dual coating of swellable and rupturable polymers on glipizide loaded MCC pellets for pulsatile delivery: formulation design and in-vitro evaluation. Int J Pharm 2011; 419(1-2): 121-30.
[32]
Deshmukh R, Naik J. Diclofenac sodium-loaded Eudragit® microspheres: optimization using statistical experimental design. J Pharm Innov 2013; 8: 276-87.
[33]
Deshmukh RK, Naik JB. Optimization of sustained release aceclofenac microspheres using response surface methodology. Mater Sci Eng C 2015; 48: 197-204.
[34]
Deshmukh R, Naik J. The impact of preparation parameters on sustained release aceclofenac microspheres: A design of experiment. Adv Powder Technol 2015; 26: 244-52.
[35]
Waghulde M, Naik J. Poly-e-caprolactone-loaded miglitol microspheres for the treatment of type-2 diabetes mellitus using the response surface methodology. J Taibah Univ Med Sci 2016; 11(4): 364-73.
[36]
Lokhande A, Naik J, Mishra S, Kulkarni R. Development of sustained release micro/nano particles using different solvent emulsification techniques: a review. Int J Pharma Bio Sci 2012; 3(4): 573-90.
[37]
Sai Ananth. Indian Pharmacopoeia. Ghaziabad: Indian Pharmacopoeia Commission 2007.
[38]
Joshi A, Patil CC, Shiralashetti SS, Kalyane NV. Design, characterization and evaluation of Eudragit microspheres containing glipizide drug. Invention Today 2013; 5: 229-34.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 3
Year: 2019
Page: [232 - 242]
Pages: 11
DOI: 10.2174/2468187309666190620145438
Price: $58

Article Metrics

PDF: 18
HTML: 2
EPUB: 1
PRC: 1

Special-new-year-discount